The TGA is aware of a report that intravenous high-dose vitamin C may be beneficial in the management of a COVID-19 infection.
We have investigated this report and found there is no robust scientific evidence to support the usage of this vitamin in the management of COVID-19.
No published studies were found for the usage of this product for COVID-19.
Two recently published open-label studies relating to the use of vitamin C in other types of infections, associated with septic shock and acute respiratory distress syndrome (ARDS), were identified and reviewed. In both of these studies, where vitamin C was used as monotherapy (used alone) or in combination with other products, there was no clear evidence of benefit. It cannot be concluded that intravenous vitamin C is an effective treatment of ARDS (resulting from COVID-19, or otherwise).
More research is needed before any recommendation for the use of intravenous vitamin C in the treatment of COVID-19 can be made.
The public should be reassured that there are many organised, scientific research studies being fast-tracked on therapy for COVID-19, both locally and internationally. Obtaining good evidence in the management of the current COVID-19 pandemic is essential in ensuring public safety.
